



**SYNCOM**  
Healthcare Limited

Date: 14.08.2018

To, The Corporate Relationship Department, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To, The Secretary, National Stock Exchange of India Limited, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai 400051
BSE Scrip Code:533157	NSE Scrip : SYNCOM ISIN No.: INE602K01014

**Subject: Outcome of Board Meeting held on 14<sup>th</sup> August 2019 in terms of Regulations 30 of SEBI (Listing Obligation and Disclosure Requirement), 2015**

Dear Sir,

Pursuant to Regulation 33 and Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors at its meeting held today i.e. Wednesday, 14<sup>th</sup> August, 2019, have amongst other matters considered, approved and taken on record the following matters:

1. Statement of Un-Audited Financial Results (Standalone) for the first quarter ended 30th June, 2019(attached);
2. Limited Review Report for the first quarter ended 30<sup>th</sup> June, 2019(attached);

The Meeting of the Board of Directors commenced at 03:00 P.M. and concluded at 06:40 p.m.

Request you to take the same on record.

For Syncom Healthcare Limited

  
**Farida Bhatia**  
Company Secretary



CIN : L51397MH2002 PLC136652



Regd. Office : 502 Advent Atria, Chincholi Bunder, Malad (W)  
Mumbai - 400064 INDIA. Tel : +91 (022) 2881 3796 / 97

Works : D - 42 IIE Sidcul Selaqui, Dehradun - 248197 Uttarakhand, INDIA  
Tel : +91 07060008770 / 07060088770 Website : www.syncom.in



STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED JUNE, 2019					
(Rs. in Lakh)					
Sr. No	Particulars	3 months end 30-06-2019 (Unaudited)	3 months end 31-03-2019 (Audited)	3 months end 30-06-2018 (Unaudited)	Year ended 31-03-2019 (Audited)
1	<b>Income</b>				
a	Revenue from operations	1,217.33	1,168.85	1,292.13	5,707.43
b	Other income	3.81	2.85	7.51	27.58
	<b>Total income</b>	<b>1,221.14</b>	<b>1,171.70</b>	<b>1,299.64</b>	<b>5,735.01</b>
2	<b>Expenses</b>				
a	Cost of materials consumed	412.62	731.06	597.81	3,218.30
b	Purchases of stock-in-trade	-	-	-	-
c	Changes in inventories of finished goods, work-in-progress and stock-	281.96	9.79	142.96	113.39
d	Employee benefit expense	267.85	273.21	286.40	1,160.72
e	Finance costs	8.33	28.58	4.24	41.46
f	Depreciation, depletion and amortisation expense	57.18	71.23	72.89	293.22
g	Other Expenses	271.84	303.45	340.46	1,402.78
	<b>Total expenses</b>	<b>1,299.78</b>	<b>1,417.33</b>	<b>1,444.77</b>	<b>6,229.86</b>
3	<b>Total profit before exceptional items and tax</b>	<b>(78.64)</b>	<b>(245.63)</b>	<b>(145.13)</b>	<b>(494.85)</b>
4	<b>Exceptional items</b>	-	650.64	(7.70)	642.54
5	<b>Total profit before tax</b>	<b>(78.64)</b>	<b>(896.27)</b>	<b>(137.42)</b>	<b>(1,137.39)</b>
6	<b>Tax expense</b>				
a	Current tax	-	-	-	-
b	Deferred tax	-	-	-	-
	<b>Total tax expenses</b>	-	-	-	-
7	<b>Total profit (loss) for period</b>	<b>(78.64)</b>	<b>(896.27)</b>	<b>(137.42)</b>	<b>(1,137.39)</b>
8	<b>Other comprehensive income net of taxes</b>				
(A)(i)	Items that will not be reclassified to Profit & Loss	-	(4.38)	-	(4.38)
(A)(ii)	Income Tax relating to items that will not be reclassified to Profit &	-	-	-	-
(B)(i)	Items that will be reclassified to Profit & Loss	-	-	-	-
(B)(ii)	Income Tax relating to items that will be reclassified to Profit & Loss	-	-	-	-
	<b>Total other comprehensive income net of taxes</b>	-	(4.38)	-	(4.38)
9	<b>Total Comprehensive Income (loss) for the period</b>	<b>(78.64)</b>	<b>(891.89)</b>	<b>(137.42)</b>	<b>(1,133.01)</b>
10	<b>Details of equity share capital</b>				
a	Paid-up equity share capital	4,000.00	4,000.00	4,000.00	4,000.00
b	Face value of equity share capital	10.00	10.00	10.00	10.00
11	<b>Other Equity</b>	<b>(4,168.95)</b>	<b>(4,090.31)</b>	<b>(2,952.90)</b>	<b>(4,090.31)</b>
12	<b>Earnings per share in Rs.</b>				
i	Basic earnings (loss) per share from continuing operations in Rs.	(0.20)	(2.23)	(0.34)	(2.83)
ii	Diluted earnings (loss) per share from continuing operations in Rs.	(0.20)	(2.23)	(0.34)	(2.83)
*EPS is not annualized for the quarter ended and half year ended figures.					
NOTE 1					
a. The above financial results for the quarter / year ended June 30, 2019 were reviewed by the Audit Committee on 14th August, 2019 and thereafter approved and taken on record by the Board of Directors at their meeting held on 14th August, 2019.					
b. The statement has been prepared in accordance with the Companies ( Indian Accounting Standard ) Rules, 2015 (Ind AS) prescribed under section 133 of Companies Act, 2013 and other recognised accounting practices and policies and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015.					
c. As per the requirements of Ind AS-108, no disclosure is required as the Company is operating in single business segment i.e. "Pharmaceutical Formulations"					
d. The unaudited Standalone financial results of the Company for the quarter ended June 30, 2019 are available on the Company's website i.e www.syncomhealthcare.com and also available on website of stock exchange i.e. www.bseindia.com and www.nseindia.com					
e. Previous quarter figures have been regrouped / rearranged wherever considered necessary.					
2	The Bank of India in its capacity of financial creditor had filed a petition under insolvency and bankruptcy code 2016 with national company law tribunal (NCLT) against Syncom Healthcare Ltd. The next date of hearing is 14.08.2019				

For Syncom Healthcare Limited



Place : Mumbai  
Date : 14.08.2019



Ajay Bankda  
Managing Director

CIN L51397MH2002 PLC136652



Regd. Office : 502 Advent Atria, Chincholi Bunder, Malad (W)

Mumbai - 400064 INDIA. Tel : +91 (022) 2881 3796 / 97

Works : D - 42 IIE Sidcul Selaqui, Dehradun - 248197 Uttarakhand, INDIA

Tel : +91 07060008770 / 07060008770 Website : www.syncom.in





# S. G. KABRA & CO.

## CHARTERED ACCOUNTANTS

Wavell House, 1st Floor, 1st Dhobi Talao Lane, Mumbai - 400 002.

Tel.: 2201 0708 / 2200 4533 • Fax : 2200 1497 • E-mail : info@sgkabra.com • Website : www.sgkabra.com

### Limited review Report

Review report to Board of Directors,

#### **Syncom Healthcare Limited**

We have reviewed the accompanying statement of unaudited financial results of **M/s Syncom Healthcare Limited** for the period ended June 30<sup>th</sup> 2019. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



## 1. Matter of Emphasis

*We draw attention to the following matters:*


- i. *Note no. 02 to the Audited Results, wherein it is stated that CIRP has been filed in case of the company by Financial creditors i.e. Bank of India under provisions of the Insolvency and Bankruptcy Code, 2016. Next hearing is scheduled on 14.08.2019.*
- ii. *The Company has continued to default in repayment of dues to the Bank of India since December 2016. The said account has been classified as Non-performing Assets (NPA) by the Bank.*
- iii. *The Company is yet to comply with reporting requirements for making full provision against investment made in its wholly owned subsidiary, during the Financial Year 2017-18 in terms of Reserve Bank of India Master Direction – Direct Investment by residents in JV/WOS abroad vide reference RBI/FED/2015-16/10FED Master Direction No. 15/2015-16.*

Our Opinion is not qualified in respect of point (i) to (iii) above.

### **FOR S G Kabra & COMPANY**

Chartered Accountants

Firm Registration No. 104507W



**MALVIKA MITRA**

Partner

Membership No. 44105

Place of signature: Mumbai

Date: 14/08/2019

UDIN: